Peptides from donor major histocompatibility complex (MHC) molecules were examined for their activation of allogeneically primed T cells. After immunization with either allogeneic spleen cells or a skin allograft, primed T cells proliferate in response to peptides derived from polymorphic regions of a and B chains of dass II allo-MHC molecules. The results demonstrate that presentation of donor-MHC peptides by host-derived antigen-presenting cells is a common event in vivo. Thus, self-restricted T cell recognition of processed alloantigens may play a critical role in transplantation. An in-depth understanding of this response may result in the development of additional molecular therapies to combat allograft rejection.
D
uring transplantation or aUograft rejection, determinants encoded within the MHC of the donor are recognized by T lymphocytes of the recipient. This recognition results in a potent immunological reaction in which donor cells are rapidly and specifically killed, and the graft is destroyed (1, 2) . It is generally accepted that T cells recognize foreign antigens in the form of peptides presented in association with self-MHC molecules. However, the molecular basis for the recognition of the allogeneic target is still controversial. Three nonexclusive models for the target structure that is recognized by alloreactive T lymphocytes have been proposed: (a) alloreactive T cells recognize polymorphic motifs present on the intact allo-MHC molecule, regardless of peptides bound to them; (b) self-(recipient) or allo-(donor) derived peptides interact with the native aUo-MHC molecules to create a series of new determinants recognized by T cells; (c) the allo-MHC molecules are processed into peptides and presented by self-MHC molecules to specific T cells (3, 4) . In this report, we provide evidence for the third alternative.
Materials and Methods
Peptides. Peptides were synthesized in the Norris Cancer Center Microchemistry Laboratory (USC) with an automated peptide synthesizer (430A; Applied Biosystems Inc., Foster City, CA) using modified Merrifield chemistry. These peptides were also used in the studies reported in reference 5.
T Cell Proliferation. B10.A (H-2'), BALB/c (H-2d), and SJL/J (H-2') mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred at UCLA. BALB/c and SJL/J mice were immunized in the foot pads with 2 x 107 irradiated sphnocytes in 25/~1, along with 25 #1 of CFA (Difco Laboratories, Detroit, MI) on the dorsal surface of the foot. Popliteal lymph node cells and splenocytes were obtained 10 d later, and used in antigen-induced proliferation assays. Cell suspensions were cultured in 0.2 ml of serum-flee HL-1 medium (Ventrex, Portland, ME), containing 2 mM glutamine in 96-weU plates for 4 d (5 x 10 s cells/well). Proliferation was assessed by the incorporation of I/~Ci [3H]thymidine during the last 18 h of culture.
Skin Grafts. SJL/J and BALB/c mice were anesthetized, and then engrafted on the left side of the back with back skin (1-cm disk) from B10.A mice, according to the technique described by Billingham and Medawar (6) .
Results and Discussion
The molecular identity of the target structure recognized by T cells during an in vivo aUoresponse leading to graft rejection is obscure. To address this issue, BALB/c (H-2 d) and SJL/J (H-2 ~) mice were primed with B10.A (A k, Ek)-irradiated splenocytes. Lymph node T cell proliferation was tested 10 d later in response to peptides from polymorphic regions of the ot and B chains of the A k class II molecule. As shown in Fig. 1 A, three MHC class II peptides, A~1-18, A~68-81, and A~1-16, elicited strong and dose-dependent T cell proliferation in SJL mice while two peptides, A~49-63 and A~58-71, were nonstimulatory. In contrast, in cultures from BALB/c mice primed with B10.A-irradiated splenocytes, only peptides A~1-16 and A~58-71 induced in vitro T cell proliferative responses (Fig. 1 B) . It is of interest that two of these peptides, A~68-81 and A~58-71, cannot bind to B10.A To determine whether analogous responsiveness to allo-MHC peptides is induced during allograft rejection, BALB/c and SJL mice were grafted with skin from B10.A animals. 10 d after the transplantation, splenocytes of the recipients were tested for in vitro proliferation to the A k peptides. As shown in Fig. 2 , SJL/J mice responded to A~1-18 while BALB/c mice responded to A~58-71, as was observed for immunizations performed with Ak-expressing allogeneic cells. It is notable that A~1-16 and A~68-81 no longer triggered T cell responses in SJL/J and BALB/c, respectively, after skin grafting, in contrast to splenocyte injection. Spleen cells from normal untreated mice and from B10.A mice that received an autograft with B10.A skin did not proliferate in response to the same class II MHC peptides (data not shown). Direct immunization of BALB/c and SJL mice with the Ak-derived peptides resulted in T cell proliferation to the same determinants as after immunization with allogeneic cells. Moreover, this approach revealed an additional determinant on the A k molecule that was undetected after immunization with allogeneic cells (Table 1) . A~49-63 was clearly immunogenic in SJL mice but could not elicit a T cell response in mice primed with splenocytes or with a skin graft. This peptide can be considered to contain a nondominant or cryptic determinant that is not produced efficiently during processing. In this sense, MHC molecules are similar to other protein antigens (e.g., lysozyme) which contain both dominant and cryptic determinant regions (7) . It is noteworthy that upon skin grafting, only one of the four, or one of the two, potentially immunogenic peptides is presented in SJL/J and BALB/c, respectively; presumably, these are the most dominant determinants. This result indicates that the method of immunization influences the nature of the determinants recognized by T cells on a multideterminant antigen and suggests that during the process of skin graft rejection, because of less efficient processing, only the predominant determinants will be presented to induce T cell proliferation.
The ability to recall responses with peptides in vitro after in vivo priming with intact cells or with skin grafting dearly indicates that donor MHC class II processing and peptide presentation occur during the course of an in vivo allogeneic response. The proliferative responses to the two peptides A~68-81 and A~58-71, which failed to bind to donor A k or E k MHC molecules, must have been presented by the recipient (H-2 ~ or H-2 a) MHC molecules. This demonstrates that one portion of the in vivo alloresponse to these alIo-MHC peptides is restricted to the MHC molecules of the recipient. In the case of A~1-16, we cannot exclude the possibility that this MHC class II peptide was presented in association with the donor-derived class II MHC molecules (8) . However, this is unlikely since we have shown that this peptide is not effectively processed in situ and is not presented by A~-bearing APC of the donor (5).
The molecular basis of allorecognition has been the subject of intense investigation, especially the characterization of the target structures recognized by cloned T lymphocytes. In several instances, CD4 + aUoreactive T lymphocytes play a crucial role in the alloresponse and have been shown to be sufficient for graft rejection (9, 10). One set of such studies on the topology of the target of alloreactive clones used singlesite mutations to modify the reactivity of particular clones (4, 11, 12) . It has been observed that amino acids located at a distance in the primary sequence could influence TCK recognition and/or peptide binding only when they were mutated simultaneously, supporting a model in which alloreacrive T lymphocytes recognize spatially distinct residues on the o~ and B chains of the intact allo-MHC molecule (4, 11, 12) . Alternatively, any modification of the structure of the allo-MHC target molecule could have also affected its processing and its hter presentation in the form ofMHC peptides.
It has been recently reported that donor MHC class I-derived peptides, in association with class I molecules or class II molecules, can be recognized by aUoreactive cytotoxic cells (13) (14) (15) or CD4 + alloreactive T lymphocytes (16), respectively. Here we have shown that during in vivo alloresponses, determinants on foreign MHC molecules can be presented to T cells in the form of peptides associated with self-MHC molecules. Arnold et al. (17) recently showed that mice expressing a class I (K k) transgene, although tolerant to allogeneic MHC peptide fragments presented in association with self-MHC dass I molecules (Db), reacted at high frequency to the membrane form of the allo-MHC molecules. These results indicate that both membrane-bound intact allo-MHC molecules and allo-MHC peptides presented in the context of a self-MHC restriction element are suitable targets in allorecognition.
How crucial is donor MHC peptide presentation by recipient MHC molecules in the actual rejection process, as compared with T cell responses directed against the intact donor MHC molecules? It is well established that after transplantation, the passenger leukocytes of the donor (macrophages, Langerhans, and dendritic cells) leave the graft and can be found in the draining lymph nodes and spleen of the recipient (18) . These bone marrow-derived, donor class II-positive cells then prime recipient T cells that recognize the intact allogeneic MHC molecules present on their surface. After recognition of the native allo-antigen, primed T cells of the recipient can infiltrate the graft and secrete lymphokines. For example, IFN-3/induces further class II expression on epithelial cells of the graft (19) . After the passenger leukocytes have left the graft, these epithelial cells should be the only allogeneic Ia-expressing cells in the transplant. Interestingly, such non-bone marrow-derived class II-bearing cells have been demonstrated to imprint nonresponsiveness on sensitized T cell clones rather than triggering alloreactive T cell responses (20, 21) . We surmise that recognition of native allo-MHC molecules is only critical for initiation of the rejection but it cannot be the mechanism for maintaining the rejection. Instead, host-derived macrophages and other class II-posirive inflammatory cells infiltrate the graft (18) , process donor MHC molecules, and present these allo-MHC peptides in the context of self-MHC class II. This mechanism should eventuate in completing the rejection by providing help for the production of donor-directed antibodies.
The results presented in this article demonstrate that donor class II-derived peptides can be presented by recipient MHC molecules, a process that may play a critical role in the rejection of the allograft. With respect to the therapy, while at an early stage in the rejection process, antigen presentation by donor MHC class II molecules might be an effective target; at a later point, blocking of recipient MHC class II molecules with antibodies or peptides may be an important factor in preventing the rejection.
